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From 19th Annual SCMR Scientific Sessions Los Angeles, CA, USA. 27-30 January 2016 Background ST2, a member of the interleukin-1 receptor family, has been shown to be independently associated with myocardial strain and adverse cardiac events in patients with both ST-elevation and non-ST elevation myocardial infarction (MI). We sought to determine whether highdose omega-3 fatty acid therapy (O-3FA) would reduce serum levels of ST2 following acute MI and whether ST2 levels correlated directly with measures of diffuse myocardial fibrosis within non-infarcted myocardium.
Methods
We evaluated 358 patients who were enrolled in a randomized, double-blinded, placebo-controlled trial of high-dose O-3FA therapy post acute MI. All patients underwent 3T CMR (Tim Trio/Verio, Siemens, Germany) and evaluation of serum biomarkers at enrollment and after 6-months of randomized study therapy. Patients were followed for adverse cardiac events by study physicians at 6-month intervals thereafter.
Results
Patients who received O-3FA treatment were more likely to have a history of coronary bypass surgery than placebo patients (p = 0.02), otherwise there were no baseline differences between treatment arms. ST2 levels were significantly reduced by O-3FA therapy as compared with placebo ( Figure 1) . By intention-to-treat analysis, O-3FA treatment was associated with a -7.9% reduction of ST2 (P = 0.03), and in adjusted analysis for covariates by -8.0% (P = 0.03). Amongst O-3FA treated patients, reduction of ST2 demonstrated a strong correlation with reduction of extracellular volume fraction within non-infarcted myocardium (r = 0.65, P < 0.0001, Figure 2 ). Baseline ST2 levels were the strongest unadjusted predictor (HR 5.2, 95% confidence interval 2.3-11.7, p < 0.0001) for all-cause mortality and congestive heart failure after a median of 2.3 years of follow-up. 
Conclusions
Serum ST2 level following acute MI is a strong prognostic marker of post-MI death and congestive heart failure. O-3FA treatment reduced ST2 levels, which were strongly correlated with reduction of the extracellular volume fraction within non-infarcted myocardium. ST2 may serve as a non-invasive serum biomarker of myocardial fibrosis, as well an independent predictor of adverse cardiac events following acute MI. 
